{
    "clinical_study": {
        "@rank": "104024", 
        "arm_group": [
            {
                "arm_group_label": "A: Bitopertin 30 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "B: Bitopertin 10 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "C: Placebo", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will\n      evaluate the efficacy and safety of bitopertin (RO4917838) in combination with selective\n      serotonin reuptake inhibitors (SSRI) in patients with obsessive-compulsive disorder.\n      Patients will be randomized to receive either bitopertin 30 mg or bitopertin 10 mg or\n      placebo orally daily in addition to their background therapy with an SSRI. Anticipated time\n      on study treatment is 16 weeks."
        }, 
        "brief_title": "A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive-Compulsive Disorder", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obsessive-Compulsive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 65 years of age\n\n          -  Primary diagnosis of obsessive-compulsive disorder (OCD) as per Diagnostic and\n             Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)\n\n          -  On a stable dose of selective serotonin reuptake inhibitor (SSRI) for at least 8\n             weeks prior to screening an between screening and Day 1\n\n          -  An insufficient response to current treatment with an SSRI given at an adequate dose\n             for at least 12 weeks prior to Day 1\n\n          -  Females who are not postmenopausal or surgically sterile must agree to use two\n             adequate methods of contraception as defined by protocol from the start of screening\n             until 90 days after the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Primary OCD symptom of hoarding\n\n          -  More than two unsatisfactory trials within the last 2 years with different serotonin\n             reuptake inhibitors (not including the current treatment with an SSRI) given in an\n             adequate dose for at least 12 weeks\n\n          -  Failure of more than one augmentation therapy or have had more than one augmentation\n             therapy used in conjunction with an SSRI\n\n          -  Recently initiated (within the last 6 months) or current behavioral therapy\n             (cognitive behavioral therapy or exposure response prevention therapy)\n\n          -  Any primary DSM-IV-TR Axis I disorder other than OCD\n\n          -  Current or prior history of bipolar disorder, schizophrenia or other psychotic\n             disorders, schizoaffective disorder, autism or autistic spectrum disorders,\n             borderline personality disorder, or Gilles de la Tourette syndrome\n\n          -  Any eating disorder within the last 6 months\n\n          -  History od substance dependence and/or substance abuse in the last 6 months, with the\n             exception of nicotine\n\n          -  Previous treatment with bitopertin or another GlyT-1 inhibitor\n\n          -  Positive urine drug screening for cannabis, amphetamines (including MDMA/ecstasy),\n             cocaine, barbiturate, and/or opiates\n\n          -  Prior or current general medical condition that may impair cognition or other\n             neuropsychiatric functioning\n\n          -  Body mass index <18.5 kg/m2 or >40 kg/m2\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674361", 
            "org_study_id": "WN28137"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "A: Bitopertin 30 mg", 
                    "B: Bitopertin 10 mg"
                ], 
                "description": "30 mg (Arm A) or 10 mg (Arm B) orally daily, 16 weeks", 
                "intervention_name": "bitopertin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C: Placebo", 
                "description": "orally daily, 16 weeks", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Serotonin Uptake Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-2200"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33701"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33613"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55454"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63118"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norristown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19403"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF RO4917838 IN COMBINATION WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH OBSESSIVE COMPULSIVE DISORDER", 
        "overall_contact": {
            "email": "genentechclinicaltrials@druginfo.com", 
            "last_name": "Please reference Study ID Number: WN28137 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in total score on Yale-Brown Obsessive Compulsive Scale (Y-BOCS)", 
            "safety_issue": "No", 
            "time_frame": "in 12 weeks between baseline and Week 16"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674361"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Clinical Global Impression of Severity (CGI-S) score", 
                "safety_issue": "No", 
                "time_frame": "in 12 weeks between baseline and Week 16"
            }, 
            {
                "measure": "Rate of responders according to changes in Y-BOCS and CGI-C", 
                "safety_issue": "No", 
                "time_frame": "in 12 weeks between baseline and Week 16"
            }, 
            {
                "measure": "Change in global social functioning: Sheehan Disability Scale (SDS)", 
                "safety_issue": "No", 
                "time_frame": "in 12 weeks between baseline and Week 16"
            }, 
            {
                "measure": "Change in Obsessive Compulsive Inventory-Revised (OCI-R) score", 
                "safety_issue": "No", 
                "time_frame": "in 12 weeks between baseline and Week 16"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "in 12 weeks between baseline and Week 16"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}